Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers

Myriad Genetics' MRD platform shows early promise in cancer recurrence detection studies.

What the company is saying

Myriad Genetics, Inc. is highlighting new interim data from the MONSTAR-SCREEN-3 study, positioning its whole-genome sequencing-based Precise MRD™ platform as a potentially transformative tool for ultra-sensitive molecular residual disease detection in resectable colorectal and pancreatic cancers. The company emphasizes the ability of its test to detect circulating tumor DNA (ctDNA) before clinical recurrence, with a median lead time of four months, and notes that more than half of ctDNA-positive patients were identified at ultra-sensitive levels below 100 parts per million. For pancreatic cancer, Myriad reports technical success in creating personalized panels for all evaluable patients, with half reaching the maximum 1,000-variant panel. The announcement is framed as a scientific milestone, with data to be presented at the European Society for Medical Oncology Congress on October 25, 2026. Dale Muzzey, Ph.D., Chief Scientific Officer, and Takayuki Yoshino, MD, PhD, principal investigator, are cited to reinforce the clinical relevance and potential impact of the findings. The tone is optimistic, focusing on the platform’s potential to improve post-surgical monitoring and risk stratification, but stops short of claiming regulatory approval or commercial adoption.

What the data suggests

The disclosed data show that ctDNA was detected prior to clinical recurrence in all observed colorectal cancer recurrence events, with a median lead time of four months. More than half of post-surgical ctDNA-positive patients were identified at ultra-sensitive levels, defined as below 100 parts per million. In the pancreatic cancer cohort, personalized panel creation was successful for all evaluable patients, with half achieving the maximum 1,000-variant panel. Patients with MRD detected one month after surgery had significantly worse recurrence-free survival than those without detectable MRD, but no specific survival rates, hazard ratios, or p-values are provided. The announcement lacks detailed quantitative performance metrics such as sensitivity, specificity, or comparative data versus standard surveillance. The evidence supports technical feasibility and early clinical association but does not establish superiority or clinical utility over existing methods. The findings are scheduled for imminent presentation at ESMO, suggesting ongoing data maturation.

Analysis

The announcement is framed with positive language, emphasizing the 'potential' and 'clinical value' of Myriad Genetics' Precise MRD platform based on interim data from the MONSTAR-SCREEN-3 study. While several realised facts are disclosed—such as ctDNA detection prior to recurrence, median lead time, and technical success in panel creation—many key claims remain forward-looking, focusing on the platform's possible future impact on patient management and clinical outcomes. The data presented are promising but lack detailed quantitative performance metrics (e.g., sensitivity, specificity, statistical significance), and there is no disclosure of financial, commercial, or regulatory milestones. The benefits are positioned as imminent (ESMO presentations in three days), but the translation to clinical adoption or revenue is not addressed. There is no indication of a large capital outlay or immediate earnings impact. The gap between narrative and evidence lies in the extrapolation from early clinical findings to broader clinical utility without supporting commercial or regulatory data.

Risk flags

• ●The absence of detailed quantitative performance metrics—such as sensitivity, specificity, or statistical significance—limits the ability to assess whether the Precise MRD platform offers a meaningful improvement over current clinical practice. Without these data, claims of clinical value remain provisional.
• ●The announcement does not address regulatory or reimbursement pathways, leaving uncertainty about the timeline and likelihood of commercial adoption. This gap introduces execution risk between promising clinical data and realized market impact.
• ●The data are from an ongoing study and represent interim findings, which may not be predictive of final outcomes. Early technical success and associations may not translate into regulatory approval or widespread clinical uptake without further validation.

Bottom line

This update signals technical and early clinical progress for Myriad Genetics’ Precise MRD™ platform in detecting molecular residual disease post-surgery for colorectal and pancreatic cancers. The most concrete findings are ctDNA detection preceding clinical recurrence by a median of four months and technical success in panel creation, with half of pancreatic cancer patients reaching a 1,000-variant panel. However, the lack of detailed performance statistics or regulatory milestones means the clinical and commercial impact remains unproven. Investors should view this as a scientific milestone rather than a commercial inflection point. The next critical disclosures would be robust performance metrics, regulatory submissions, or evidence of clinical adoption. The key takeaway is that while the platform shows promise, its ultimate value will depend on forthcoming data and regulatory progress.

Announcement summary

(NASDAQ:MYGN) Myriad Genetics, Inc. announced new data from the ongoing MONSTAR-SCREEN-3 study, demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform for ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers. The findings will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. Dale Muzzey, Ph.D., Chief Scientific Officer of Myriad Genetics, stated that the data reinforce the potential of Precise MRD to enable more sensitive and personalized monitoring in cancers where recurrence is difficult to identify until disease burden is higher. The MONSTAR-SCREEN-3 data highlight the performance of the WGS-based Precise MRD platform in resectable colorectal cancer and resectable pancreatic cancer. The study evaluated whether personalized, ultra-sensitive MRD testing could identify patients at higher risk of recurrence after surgery and provide earlier molecular insight than conventional clinical surveillance. In resectable colorectal cancer patients, ctDNA detected one month after surgery was strongly associated with disease progression. ctDNA was detected prior to clinical recurrence in all observed recurrence events, with a median lead time of four months. More than half of post-surgical ctDNA-positive patients were identified at ultra-sensitive levels, defined as below 100 parts per million. In resectable pancreatic cancer, personalized panel creation was successful for all evaluable patients, with half achieving the maximum 1,000-variant panel. Patients with MRD detected one month after surgery had significantly worse recurrence-free survival than those without detectable MRD. Takayuki Yoshino, MD, PhD, National Cancer Center Hospital East and principal investigator of the MONSTAR-SCREEN-3 study, stated that the findings support the clinical value of ultra-sensitive MRD assessment for guiding follow-up strategies in patients with resectable cancers. The MONSTAR-SCREEN-3 findings will be featured in two ESMO presentations: 'Clinical Significance of Ultrasensitive ctDNA Detection for Molecular Residual Disease Assessment in Resectable Colorectal Cancer in MONSTAR-SCREEN-3' (Session: Proffered Paper 1: Basic Science and Translational Research, Room: Burgos Auditorium - Hall 3, Date: Sunday, October 25, 2026, Time: 2:45 - 4:15pm) and 'Molecular Residual Disease Detection for Resectable Pancreatic Cancer Using a Whole-Genome Sequencing-Based ctDNA Assay: Initial Findings from MONSTAR-SCREEN-3' (Poster Number: 3138P, Date: Sunday, October 25, 2026, Time: 12:00 - 12:45pm).

Disagree with this article?